Loading


Takeda Announces the Revision of the Consolidated Financial Forecasts for Fiscal 2011



The Company's Official Page
http://www.takeda.com/press/article_43612.html
Back To Previous Page

Main contents starts here

Press Releases

November 4, 2011

Takeda Pharmaceutical Company Limited

Takeda Announces the Revision of the Consolidated Financial Forecasts for Fiscal 2011

Osaka, Japan, November 4, 2011 – Takeda Pharmaceutical Company Limited (“Takeda”) announced today a revision to the consolidated financial forecasts for fiscal year ending March 31, 2012, that were previously announced on July 29, 2011. The revision was made based on the recent trends in business performance.

1. Revised Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2012
Net Sales Operating
Income
Ordinary
Income
Net Income Earnings
Per Share
“EPS”
(Millions of yen) (Millions of yen) (Millions of yen) (Millions of yen) (Yen)
Previous Forecast(A) 1,450,000 390,000 395,000 250,000 316.71
Revised Forecast (B) 1,540,000 270,000 270,000 170,000 215.36
Change (B-A) 90,000 (120,000) (125,000) (80,000) -
Change (%) 6.2 (30.8) (31.6) (32.0) -
Reference:
Consolidated Financial
Results for Fiscal Year
Ending March 31, 2011
1,419,385 367,084 371,572 247,868 314.01

2. Reasons for Revision
The consolidated financial forecasts for fiscal year ending March 31, 2012, have been revised from the previous forecasts (announced at 1st quarter of fiscal 2011 financial results announcement on July 29, 2011), taking the current results into consideration and reflecting a review of foreign exchange rates, in addition to the effect of acquisition of Nycomed. The details can be found at the following URL.
(Website of the Company)

http://www.takeda.com/investor-information/quarterly-results/index_869.html

(Website of the Tokyo Stock Exchange, part of listed company information)

http://www.tse.or.jp/tseHpFront/HPLCDS0101E.do

The revised forecast for FY2011 includes the effect of acquisition of Nycomed. However, the amount of valuation/allocation for Nycomed’s assets/liabilities and the accounting treatment for the amortization method and its duration may be changed within one year from the acquisition date, according to the business combination accounting standards. The final amount will be settled through the audit by our independent auditor. This forecast includes the Nycomed’s profit and loss impact for 2nd half of fiscal 2011 only, because the acquisition was completed at the end of September 2011.

###

Skip sub navigation



Related Latest News
"Takeda Pharmaceutical Company Limited" more
"Pharmaceuticals" Listed Companies more
"Pharmaceuticals" Non-listed Companies more
"Osaka" Companies more

WARNING: (1) Because this website uses a computer program to automatically collect and display press-release text information, errors or inaccuracy may occur. Double-check with information on these companies' official websites. (2) A press release may contain facts, figures and preliminary forward-looking statements which are subject to change.
Latest Press Release Search


Fukushima | power supply | cloud | solar
*NOTE: Recommended keywords shown above.
Your Most Recently Viewed Companies
Visit any of the company pages in JPubb, and your most recently viewed companies will automatically show up here.